

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



Final Appraisal Recommendation

Advice Number: 2412 – September 2012

Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension

Limited submission by Nova Laboratories Ltd

Recommendation of the All Wales Medicines Strategy Group

Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension is recommended as an option for use within NHS Wales for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.

Additional notes:

- AWMSG is of the opinion that mercaptopurine (Xaluprine®) 20 mg/ml oral suspension is appropriate for specialist only prescribing within NHS Wales for the indication under consideration.
- The mercaptopurine oral suspension and tablet are not bioequivalent with respect to peak plasma concentration, and therefore intensified haematological monitoring of the patient is advised on switching formulations.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1252), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in December 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 2412: Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension. September 2012.